The Hype And Hope Of Cancer Stem Cell Therapeutics
This article was originally published in Start Up
Executive Summary
A wave of recent deals demonstrates a growing belief in the potential cancer stem cells might offer for more effective cancer therapies. Some say there’s more hope and hype than science behind the activity. As the science unfolds, fundamental questions have yet to be answered about the pathway to products, especially as drug developers train their lines of sight on solid tumors.
You may also be interested in...
Erivedge May Be The Gleevec Of Hedgehog Inhibitors
FDA approval of Curis/Genentech’s hedgehog inhibitor Erivedge validates the class, but basal cell carcinoma is only the ante; cancers exploit hedgehog signaling in a variety of ways yet to be elucidated.
Erivedge BCC Approval Buoys Hedgehog Fans, But Pathway Needs Proof In Other Cancers
FDA approval of Curis/Genentech’s hedgehog inhibitor Erivedge validates the class, but basal cell carcinoma is only the ante; cancers exploit hedgehog signaling in a variety of ways yet to be elucidated.
Cancer Stem Cell Differentiation In Reverse, Spontaneously
Scientists have now shown that both normal and cancerous mammary cells may spontaneously "de-differentiate" into stem cells without any genetic manipulations. This apparently innate cellular plasticity suggests new possibilities for utilizing cultured cells both as a tool in the discovery of cancer therapies that target cancer stem cells and also as an autologous therapy in regenerative medicine.